Advertisement

Healthcare resource utilization and cost of care for Gaucher patients in Iran

  • Majid Davari
  • Azita NabizadehEmail author
  • Maliheh Kadivar
  • Akbar Abdollahi Asl
  • Peymaneh Sarkheil
Research Article
  • 20 Downloads

Abstract

Introduction

Gaucher disease (GD) is an inherited recessive enzyme deficiency with a multisystem condition. The Iranian government covers the therapeutic expenditure of GD patients as it is not affordable for the patients. The aim of this study is to identify the main components of the cost of care in Gaucher patients (GPs) in Iran.

Methods

The Gaucher patients were identified from the Iran Food and Drug Administration (IFDA) national registry database. The direct medical costs, including medication, diagnostic services, and physician visits were considered. The prices of therapeutic and diagnostic services were extracted from Iranian medical tariff book 2014–15. Iran Food and Drug Administration determined the cost of medications.

Results

164 Gaucher patients have been registered in Iran. A valid and reliable diagnostic tests are not used to identify the type of GD. The average health care cost per annum was 20,758 USD per patient, which is higher than 4 GDP per capita in Iran. Medication cost constitutes 95.2% of the total cost. The average cost of each GP was $1,473,818 in his/her total life.

Conclusion

GD is amongst the high-cost diseases and should be managed effectively. The application of oral medication for eligible GPs could improve allocative efficiency in GD management significantly. A sound, valid and reliable national clinical guideline could improve the efficiency of healthcare resources effectively. Selecting appropriate strategies for reducing the birth of a child with Gaucher, could support allocative efficiency of the limited resources effectively.

Keywords

Health care Gaucher disease Cost Resource utilization Iran 

Notes

Acknowledgements

We would like to acknowledge the IFDA staffs, particularly Dr. Zolfaghar Taghaviyan who were supportive during data collection from IFDA database.

Compliance with ethical standards

Ethical approval

The study was approved by the Faculty of pharmacy and Research Ethics Committee of the Tehran University of Medical Sciences.

Conflicts of interests

The authors declare that they have no competing interests.

References

  1. 1.
    Biegstraaten M, Van Schaik I, Aerts J, Hollak C. Non-neuronopathic’Gaucher disease reconsidered. Prevalence of neurological manifestations in a Dutch cohort of type I Gaucher disease patients and a systematic review of the literature. J Inherit Metab Dis. 2008;31(3):337–49.CrossRefGoogle Scholar
  2. 2.
    Keatinge M, Bui H, Menke A, Chen Y-C, Sokol AM, Bai Q, et al. Glucocerebrosidase 1 deficient Danio rerio mirror key pathological aspects of human Gaucher disease and provide evidence of early microglial activation preceding alpha-synuclein-independent neuronal cell death. Hum Mol Genet. 2015;24(23):6640–52.CrossRefGoogle Scholar
  3. 3.
    Machaczka M. What hematologist needs to know about Gaucher disease. Acta Haematol Pol. 2013;44:301–6.CrossRefGoogle Scholar
  4. 4.
    Zimran A. How I treat Gaucher disease. Blood. 2011;118(6):1463–71.CrossRefGoogle Scholar
  5. 5.
    Mistry P, Weinthal J, Weinreb N. Disease state awareness in Gaucher disease: a Q&A expert roundtable discussion. Clin Adv Hematol Oncol: H&O. 2012;10(6 Suppl 8):1–16.Google Scholar
  6. 6.
    Barranger JA, Brady RO, Grabowski GA, Mankin H, Mistry PK, Weinreb NJ. Position statement: National Gaucher Foundation Medical Advisory Board, January 7, 2014. Am J Hematol. 2014;89(5):457–8.CrossRefGoogle Scholar
  7. 7.
    Barton NW, Brady RO, Dambrosia JM, Di Bisceglie AM, Doppelt SH, Hill SC, et al. Replacement therapy for inherited enzyme deficiency—macrophage-targeted glucocerebrosidase for Gaucher's disease. N Engl J Med. 1991;324(21):1464–70.CrossRefGoogle Scholar
  8. 8.
    Gonzalez DE, Turkia HB, Lukina EA, Kisinovsky I, Dridi MFB, Elstein D, et al. Enzyme replacement therapy with velaglucerase alfa in Gaucher disease: results from a randomized, double-blind, multinational, phase 3 study. Am J Hematol. 2013;88(3):166–71.CrossRefGoogle Scholar
  9. 9.
    Grabowski GA, Barton NW, Pastores G, Dambrosia JM, Banerjee TK, McKee MA, et al. Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources. Ann Intern Med. 1995;122(1):33–9.CrossRefGoogle Scholar
  10. 10.
    Weinreb NJ, Charrow J, Andersson HC, Kaplan P, Kolodny EH, Mistry P, et al. Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher registry. Am J Med. 2002;113(2):112–9.CrossRefGoogle Scholar
  11. 11.
    Charrow J, Dulisse B, Grabowski G, Weinreb N. The effect of enzyme replacement therapy on bone crisis and bone pain in patients with type 1 Gaucher disease. Clin Genet. 2007;71(3):205–11.CrossRefGoogle Scholar
  12. 12.
    Wenstrup R, Roca-Espiau M, Weinreb N, Bembi B. Skeletal aspects of Gaucher disease: a review. Br J Radiol. 2002;75(suppl_1):A2–A12.CrossRefGoogle Scholar
  13. 13.
    Elstein D, Hadas-Halpern I, Itzchaki M, Lahad A, Abrahamov A. Effect of low-dose enzyme replacement therapy on bones in Gaucher disease patients with severe skeletal involvement. Blood Cell Mol Dis. 1996;22(2):104–11.CrossRefGoogle Scholar
  14. 14.
    Chen M, Wang J. Gaucher disease: review of the literature. Arch Pathol Lab Med. 2008;132(5):851–3.Google Scholar
  15. 15.
    Cox TM, Drelichman G, Cravo R, Balwani M, Burrow TA, Martins AM, et al. Eliglustat compared with imiglucerase in patients with Gaucher's disease type 1 stabilised on enzyme replacement therapy: a phase 3, randomised, open-label, non-inferiority trial. Lancet. 2015;385(9985):2355–62.CrossRefGoogle Scholar
  16. 16.
    Mignot C, Doummar D, Maire I, De Villemeur TB, Group FTGDS. Type 2 Gaucher disease: 15 new cases and review of the literature. Brain Dev. 2006;28(1):39–48.CrossRefGoogle Scholar
  17. 17.
    Weinreb NJ, Aggio MC, Andersson HC, Andria G, Charrow J, Clarke JT, et al., editors. Gaucher disease type 1: revised recommendations on evaluations and monitoring for adult patients. Seminars in hematology; 2004: Elsevier.Google Scholar
  18. 18.
    Weinreb NJ, Deegan P, Kacena KA, Mistry P, Pastores GM, Velentgas P, et al. Life expectancy in Gaucher disease type 1. Am J Hematol. 2008;83(12):896–900.CrossRefGoogle Scholar
  19. 19.
    World Health Organization (WHO). Global Health Observatory (GHO) date 2015. Available from: http://search.who.int/search?q=iran+life+expectancy&ie=utf8&site=who&client=_en_r&proxystylesheet=_en_r&output=xml_no_dtd&oe=utf8&getfields=doctype. Accessed 2 Dec 2017.
  20. 20.
    Belmatoug N, Di Rocco M, Fraga C, Giraldo P, Hughes D, Lukina E, et al. Management and monitoring recommendations for the use of eliglustat in adults with type 1 Gaucher disease in Europe. Eur J Intern Med. 2017;37:25–32.CrossRefGoogle Scholar
  21. 21.
    Smid BE, Hollak CE. A systematic review on effectiveness and safety of eliglustat for type 1 Gaucher disease. Expert Opin Orphan Drugs. 2014;2(5):523–9.CrossRefGoogle Scholar
  22. 22.
    Krug B, Schwartz I, De Oliveira FL, Alegra T, Martins NC, Todeschini L, et al. The management of Gaucher disease in developing countries: a successful experience in Southern Brazil. Public Health Genomics. 2010;13(1):27–33.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Department of Pharmacoeconomics and Pharmaceutical Administration, Faculty of PharmacyTehran University of Medical SciencesTehranIran
  2. 2.Children’s Hospital Medical CenterTehran University of Medical SciencesTehranIran
  3. 3.Endocrine Research Center, Research Institute for Endocrine SciencesShahid Beheshti University of Medical SciencesTehranIran

Personalised recommendations